Business Description
Waverley Pharma Inc
NAICS : 325412
SIC : 3741
ISIN : CA94357L1058
Compare
Compare
Traded in other countries / regions
WAVE.Canada5GZ.Germany IPO Date
2020-09-14Description
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | -1.19 | |||||
| Debt-to-Equity | -1.41 | |||||
| Debt-to-EBITDA | -1.76 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -22.63 | |||||
| Beneish M-Score | -4.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -31.6 | |||||
| 3-Year EBITDA Growth Rate | -9.4 | |||||
| 3-Year EPS without NRI Growth Rate | -32 | |||||
| 3-Year FCF Growth Rate | -39.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.33 | |||||
| 9-Day RSI | 38.64 | |||||
| 14-Day RSI | 38.74 | |||||
| 6-1 Month Momentum % | 3.33 | |||||
| 12-1 Month Momentum % | 19.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.2 | |||||
| Quick Ratio | 0.2 | |||||
| Cash Ratio | 0.03 | |||||
| Days Inventory | 93.61 | |||||
| Days Sales Outstanding | 106.94 | |||||
| Days Payable | 713.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -70.16 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 19.37 | |||||
| Operating Margin % | -298.55 | |||||
| Net Margin % | -538.74 | |||||
| FCF Margin % | -247.18 | |||||
| ROE % | -797.49 | |||||
| ROA % | -107.01 | |||||
| ROIC % | -46.6 | |||||
| ROCE % | -441.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.5 | |||||
| EV-to-EBIT | -2.13 | |||||
| EV-to-EBITDA | -2.89 | |||||
| EV-to-Revenue | 6.37 | |||||
| EV-to-FCF | -2.57 | |||||
| Earnings Yield (Greenblatt) % | -46.95 | |||||
| FCF Yield % | -94.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Waverley Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.284 | ||
| EPS (TTM) (€) | -0.031 | ||
| Beta | 1.15 | ||
| Volatility % | 101.44 | ||
| 14-Day RSI | 38.74 | ||
| 14-Day ATR (€) | 0.000535 | ||
| 20-Day SMA (€) | 0.009725 | ||
| 12-1 Month Momentum % | 19.23 | ||
| 52-Week Range (€) | 0.0065 - 0.018 | ||
| Shares Outstanding (Mil) | 54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Waverley Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Waverley Pharma Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Waverley Pharma Inc Frequently Asked Questions
What is Waverley Pharma Inc(FRA:5GZ)'s stock price today?
The current price of FRA:5GZ is €0.01. The 52 week high of FRA:5GZ is €0.02 and 52 week low is €0.01.
When is next earnings date of Waverley Pharma Inc(FRA:5GZ)?
The next earnings date of Waverley Pharma Inc(FRA:5GZ) is .
Does Waverley Pharma Inc(FRA:5GZ) pay dividends? If so, how much?
Waverley Pharma Inc(FRA:5GZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers